How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Multisite complex enhancing vaccination against Staphylococcus aureus

Organization name

Interface Entreprises-Université de Liege


The University of Liège in Belgium has developed new scaffolds based on a protein carrier which, as an adjuvant, increase the vaccinal efï¬Âcacy and neutralize virulence factors of S.aureus.    

As the actual treatments are more and more faced with resistant strains and multiple virulenceʼs factors responsible of the toxicity, there is indeed a need of alternative treatments of S.aureus.    

The University of Liège is seeking companies interested in a development collaboration or in-licensing opportunity for this novel complex which induces immune response against this bacteria.         


  • targets simultaneously major virulence factors for an increased vaccinal effect (Immunization >60-70%);      
  • while due to its structure it can be easily added to vaccinal preparation
  • can be produced in high amount which reduces production costs.          

Potential Applications    

The scaffolds may be used as antigenic source in any vaccinal preparations, for example against S.aureus.              


This protein carrier developed from anattenuated virulence factor :

  • allows to target simultaneously several virulence factors (included the protein carrier) involved in the different infection steps by S.aureus;      
  • leads to the production of antibodies which increase the bacteria coating and block the biological activity of the virulenceʼs factors;                            
  • gives high puriï¬Âcation yields;                
  • induces also immune reactions against short;                  
  • is organized in nanostructure.                                                      

Patent Status            

Pending : WO2010081875A1                                     

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries